Long-term effects of platin and anthracycline derivatives and possible prevention strategies

Frontiers of Radiation Therapy and Oncology

Volumn 37, Issue , 2002, Pages 92-100

  Hartmann, Jörg Thomas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN;

DRUG EFFECT; EAR DISEASE; HEART; HEART DISEASE; HUMAN; IATROGENIC DISEASE; INNER EAR; KIDNEY; KIDNEY DISEASE; NEOPLASM; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; REVIEW;

ANTHRACYCLINES; CISPLATIN; EAR DISEASES; HEART; HEART DISEASES; HUMAN; KIDNEY; KIDNEY DISEASES; LABYRINTH; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 0036134358     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (34)

1. Bissett D, Kunkeler L, Zwanenburg L, Paul J, Gray C, Swan IRC, Kerr DJ, Kaye SB: Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 1990;62:655-659.
2. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L: Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998;77:1355-1362.
3. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923-2932.
4. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H: Trends in cancer incidence and mortality. IARC Sci Publ 1993;121:1-806.
5. Cortes EP, Lutman G, Wanka J, et al: Adriamycin (NSC-123127) cardiotoxicity: A clinicopathologic correlation. Cancer Chemother Rep 1975;6:215-225.
6. Daugaard G, Rossing N, Rorth M: Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988;21:163-167.
7. Fjeldborg P, Sorensen J, Helkjaer PE: The long-term effect of cisplatin on renal function. Cancer 1986;58:2214-2217.
8. Groth S, Nielsen H, Sorensen JB, Christensen AB, Pedersen AG, Rorth M: Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 1986;17:191-196.
9. Hamilton CR, Bliss JM, Horwich A: The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol 1989;25:185-189.
10. Hansen SW, Groth S, Daugaard G, Rossing N, Rorth M: Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988;6:1728-1731.
11. Hansen SW, Helweg LS, Trojaborg W: Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989;7:1457-1461.
12. Hartmann JT, Fels LM, Knop F, Stolte H, Kanz L, Bokemeyer C: A randomised trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 2000;18:281-289.
13. Hartmann JT, Fels LM, Franzke A, Knop S, Renn M, Maess B, Panagiotou P, Lampe H, Kanz L, Stolte H, Bokemeyer C: Comparative study of the acute nephrotoxicity from standard dose cisplatin ± ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res 2000;20:3767-3774.
14. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C: Longterm effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 1999; 80:801-807.
15. Hartmann JT, Kanz L, Bokemeyer C: Diagnosis and treatment of patients with testicular germ cell cancer. Drugs 1999;58:257-281.
16. Hartmann JT, Knop S, Fels LM, van Vangerow A, Stolte H, Kanz L, Bokemeyer C: The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. Anticancer Drugs 2000;11:1-6.
17. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C: Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999;83:866-869.
18. Hartmann JT, von Wangerow A, Fels LM, Knop S, Stolte H, Kanz L, Bokemeyer C: A randomized trial of amifostine in patients with high dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 2001; 84:313-320.
19. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17:3333-3355.
20. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-2112.
21. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973;32:302-314.
22. MacLeod PM, Tyrell CJ, Keeling DH: The effect of cisplatin on renal function in patients with testicular tumours. Clin Radiol 1988;39:190-192.
23. Moul JW, Robertson JE, George SL, Paulson DF, Walther PJ: Complications of therapy for testicular cancer. J Urol 1989;142:1491-1496.
24. Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J: Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992;10:574-579.
25. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH: Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat Rep 1982;66:19-23.
26. Roth BJ, Einhorn LH, Greist A: Long-term complications of cisplatin-based chemotherapy for testis cancer. Semin Oncol 1988;15:345-350.
27. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D: High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12:1223-1231.
28. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A: Protective effect of the bispiperazinedione ICRF-187 against doxorubicininduced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-752.
29. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC: Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54:1269-1275.
30. Treskes M, van der Vijgh WJ: WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: A molecular approach. Cancer Chemother Pharmacol 1993;33:93-106.
31. van der Hulst RJ, Dreschler WA, Urbanus NA: High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 1988;97:133-137.
32. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
33. Wagstaff AJ, Ward A, Benfield P, Heel RC: Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989;37:162-190.
34. Schuchter LM, Merpol N, Glick JH: Radiation and chemotherapy protectors; in DeVita V Jr, Hellman H, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, ed 2, Philadelphia, Lippincott-Raven, 1997, vol 2, chap 65, pp 3087-3092.